Calquence Earns Breakthrough Therapy Designation


AstraZeneca’s BTK inhibitor Calquence won Breakthrough Therapy Designation from the U.S. FDA as a monotherapy treatment for patients with chronic lymphocytic leukemia (CLL).
Source link
Powered 4 Significance LLC © 2018 All Rights Reserved
4 Spring Hill Road * Annandale, NJ 08801 * Phone: (908) 428-8008 * Fax: (908) 428-4668
Powered 4 Significance is a subsidiary of Blue Ocean Pharma LLC
Blue Ocean Pharma LLC
Percolation Communications LLC
i.e. Strategy